1[1]Heathcote EJ. Management of Primary biliavy cirrhosis. The American Association for the study of Liver Diseases practice guidelines[J]. Hepatology ,2000,31: 1005 - 1013.
2[2]Invernizzi P, Crosignani A, Battezzati P,et al. Comparison of the clinical features and clinical course of antimitochondrial antibodypositive and negative primary biliary cirrhosis [ J ]. Hepatology,1997,25:1090 - 1095.
3[3]Van de Water J,Cooper A,Surch CD,et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis [J]. N Eng1 J Med, 1989,320:1377 -1380.
4[4]Sorensen HT, Thulstrup A, Friis S, et al. Cancer risk in patients with liver criihossis:a regisry study on 850000 person years[J]. J Hepaol, 1997,26suppl1: 101.
5[5]Leung PS, Van de Water J, Coppel RL,et al. Molecular aspects and pathological basis of primary biliary cirrhosis[J]. J Autoimmun, 1996,9:119 - 128.
7Petrovic B D, Nikolaidis P, Hammond N A, et al. Correla- tion between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis [ J ]. Dig Dis Sci, 2007,52 (12) :3499-3506.
